Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help some 150 million Americans suffering from brain disorders.When Herriot Tabuteau started a drug development company in 2012, he decided to do so differently. First, he’d focus on brain disorders, treatments for which are notoriously difficult to develop and whose efficacy can be hard to prove. And he’d be both CEO and the scientific founder, bringing to bear his dec­ades of experience investing in biotech s ...

公司近期活动安排 - 公司宣布将参加2025年10月的一系列科学与投资者会议 [1][2] - 首席执行官Daniel Vitt博士将于10月9日在Roth第四届年度医疗保健机会会议上参与小组讨论，并与首席财务官Glenn Whaley一同参加一对一投资者会议 [2] - 公司管理层将于10月23日参加H C Wainwright举办的虚拟炉边谈话 [2] 产品研发管线与临床进展 - 主要研发项目vidofludimus calcium (IMU-838)目前正处于治疗复发型多发性硬化症的3期临床试验阶段，顶线数据预计在2026年底前获得 [3] - IMU-838作为一种首创的Nurr1激活剂，兼具神经保护、抗炎和抗病毒作用，并在针对复发缓解型多发性硬化症和进展型多发性硬化症的2期临床试验中已显示出治疗活性 [3] - 另一研发资产IMU-856靶向Sirtuin 6 (SIRT6)，旨在恢复肠道屏障功能和再生肠上皮，潜在适用于乳糜泻、炎症性肠病、移植物抗宿主病及体重管理等多种胃肠道疾病 [3] - IMU-381是处于临床前测试阶段的下一代分子，正被开发用于专门解决胃肠道疾病的需求 [3] 10月科学会议数据展示 - 公司研发团队将于10月4日至7日参加柏林举办的欧洲胃肠病学周会议，并以口头报告、出版物和电子海报形式展示关于IMU-856的数据 [2] - 在胃肠病学周会议上，将展示一项1期临床研究数据，表明IMU-856对乳糜泻患者的肠道激素水平产生了积极影响 [2] - 同期将展示一份电子海报，内容关于细胞外基质重塑的生物标志物反映了IMU-856的药效学效应 [2] - 研究主管Evelyn Peelen博士将于10月5日至8日在日本千叶举办的国际神经免疫学学会第17届国际大会上，以海报形式展示vidofludimus calcium (IMU-838)的临床前数据，显示其在临床前模型中表现出神经保护迹象 [2]

合作公告概述 - RetinalGenix Technologies Inc (OTCQB: RTGN) 与 RGEN Inc 宣布建立战略合作伙伴关系，旨在推动神经退行性疾病、全身性疾病及视网膜疾病的早期检测和风险预测取得突破性进展 [1] 合作技术与方法 - 合作通过整合先进视网膜成像与临床级DNA基因分型来开发预测模型 [2][3] - 采用双管齐下的诊断模式，旨在捕获表型视网膜变化和临床相关DNA变异 [3] - 利用RetinalGenix专有的高分辨率视网膜成像平台和RGEN经CLIA认证的高通量DNA测试能力 [3] 合作目标与疾病领域 - 加速开发预测模型并促进针对年龄相关性黄斑变性、青光眼、糖尿病视网膜病变、复杂性痴呆、阿尔茨海默病和帕金森病等疾病的人群级筛查 [2] - 关键目标包括整合视网膜成像和基因型数据以开发疾病风险预测模型、识别与疾病相关的新型遗传生物标志物和表型指标、提供临床可操作的见解以及部署可扩展的慢性病筛查平台 [5][7] 战略意义与未来规划 - 该合作被认为是预测性、预防性和个性化医学领域的重大进步 [4] - 整合方法有望通过早期干预改善患者预后，并减轻医疗系统的长期负担 [4] - 下一步计划包括在初级保健机构、诊所及眼科环境中商业部署联合筛查工具，与医疗支付方合作以支持预防性护理覆盖，并将平台扩展至其他年龄相关和神经退行性疾病 [5] 公司背景 - RetinalGenix是一家眼科研发公司，致力于通过整合基因筛查、先进成像和治疗开发来革新疾病早期检测 [6] - RGEN Inc是遗传研究和测试领域的领先创新者，通过其CLIA认证实验室提供全基因组测序等服务 [7][8]

Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics. Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming. Klotho has signed a letter of intent (LOI) in this regard. The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions. Under the LOI's t ...

Biomap, a biotechnology start-up co-established by Baidu founder Robin Li Yanhong and backed by the Hong Kong government, says it has surpassed Alphabet subsidiary AlphaFold in commercialising artificial intelligence foundation models for drug discovery. Multinational pharmaceutical companies were seeing a "reverse" in the technological gap between Biomap and AlphaFold, Wei Liu, co-founder and CEO of Biomap and former CEO of Baidu Ventures, said in an interview with the South China Morning Post. "There's ...

中国新签证政策 - 中国于8月宣布并于周三推出新的K签证计划 旨在吸引全球科技人才 特别是STEM领域的年轻毕业生 他们不再需要本地雇主支持 且在入境频率和停留时间上更具灵活性[2][3] - 该政策被视为中国在技术雄心与移民政策之间寻求平衡的测试 重点吸引半导体、生物技术、清洁能源、先进制造和人工智能等关键战略领域的外国专业人才[2][8][14] - 与美国近期对H-1B签证施加10万美元申请费等限制形成对比 中国正通过更开放的姿态吸引人才以帮助其在关键技术领域追赶[8][13] 社会舆论与市场反应 - 新签证在中国社交媒体引发强烈反弹 关键词K签证一度位列微博热搜榜首 批评认为该政策偏向外国毕业生 可能滋生欺诈申请 并加剧本已紧张的就业市场压力[3][4][5] - 官方媒体对批评作出尖锐回应 驳斥其为误导和狭隘 《人民日报》社论强调中国仍缺乏提升技术优势所需的高层次人才 前《环球时报》总编辑胡锡进指出外籍人士仅占中国人口的01%至02% 远低于美国的15%[6][7] - 分析认为尽管存在公众反对 但国家资本主导的新政策将严格控制发放数量与标准 主要针对顶尖科技人才 对整体就业市场影响有限[9][11] 中国就业市场背景 - 中国就业市场持续恶化 8月份城镇失业率升至2月以来最高水平 青年失业率（不含学生）在8月飙升至189% 为2023年新统计体系实施以来的最高值[9][10] - 今年有创纪录的1220万大学毕业生进入就业市场 加剧了受教育劳动力供应充足与白领职位短缺之间的错配[10] 政策战略意图 - K签证不代表中国移民政策的全面放开 中国历史上对低技能工人入境和外国人永久居留保持严格限制 该政策是经过精密计算的战略举措 目标是战略性吸纳能增强中国竞争力的杰出个体 而非大规模招募[16][18] - 政策最终目标是依靠中国自身能力构建未来科技 吸引人才特别是面临美国企业竹天花板限制的华裔美国人 是展示中国体制优越性的机会[14][15][17] 其他经济动态 - 中国工业企业利润飙升 政府加强努力遏制过剩供应和损害企业利润的激进价格战 产能过剩问题的重组可能成为第十五个五年计划的持久主题[25] - 9月制造业活动官方指标显示收缩幅度小于预期 政府在国内需求疲软和全球贸易中断背景下加大遏制工业过剩产能的力度[26] - 中国股市因国庆假期休市 10年期国债收益率上升近2个基点至1878%[27][29]

Biotech stocks posted strong after-hours gains Tuesday, with several small-cap names rebounding despite limited news flow. Broader sentiment may have been supported by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing. Ovid Therapeutics, NeuroOne Medical, PepGen, Reviva Pharmaceuticals, and Anika Therapeutics all saw notable moves following mixed regular session action.Ovid Therapeutics Inc. (OVID) rose 7.69% in after-hours trading on Tuesday, climbing to ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of custom. ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with skin disease (hidradenitis suppurative or “HS”). The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled inv ...